Home Cart Sign in  
Chemical Structure| 203120-17-6 Chemical Structure| 203120-17-6

Structure of Laninamivir
CAS No.: 203120-17-6

Chemical Structure| 203120-17-6

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Laninamivir is a neuraminidase inhibitor that exhibits clinical efficacy for both treatment and prophylaxis of influenza virus infection, resulting from hydrolytic bioactivation into its pharmacologically active metabolite laninamivir in the pulmonary tissue.

Synonyms: R 125489

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Laninamivir

CAS No. :203120-17-6
Formula : C13H22N4O7
M.W : 346.34
SMILES Code : OC[C@@H](O)[C@H]([C@@]1([H])[C@@H]([C@H](C=C(O1)C(O)=O)NC(N)=N)NC(C)=O)OC
Synonyms :
R 125489
MDL No. :MFCD18071611
InChI Key :QNRRHYPPQFELSF-CNYIRLTGSA-N
Pubchem ID :502272

Safety of Laninamivir

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P264-P270-P271-P280-P301+P312-P302+P352-P304+P340-P305+P351+P338-P330-P332+P313-P337+P313-P362-P403+P233-P405-P501

Isoform Comparison

Biological Activity

Description
Laninamivir (R 125489) exhibits potent inhibition of influenza neuraminidase (NA), demonstrating IC50 values of 0.90 nM, 1.83 nM, and 3.12 nM for avian H12N5 NA (N5), pH1N1 N1 NA (p09N1), and A/RI/5+/1957 H2N2 N2 (p57N2), respectively [1].

In Vitro:

Cell Line
Concentration Treated Time Description References
MDCK cells 1 to 5 μM three passages screened and identified substitutions conferring resistance to laninamivir J Virol. 2019 Mar 5;93(6):e01825-18
MDCK cells 0.06–1 µM 3 days Evaluation of the inhibitory effect of Laninamivir combined with Baloxavir on H3N2 virus, showing strong synergy (268.57 µM2%) Viruses. 2024 Sep 14;16(9):1467
MDCK cells 0.06–1 µM 3 days Evaluation of the inhibitory effect of Laninamivir combined with Baloxavir on H1N1-PR8-R292K mutant strain, showing moderate synergy (72.3 µM2%) Viruses. 2024 Sep 14;16(9):1467
MDCK cells 0.06–1 µM 3 days Evaluation of the inhibitory effect of Laninamivir combined with Baloxavir on H1N1-WSN-I38T mutant strain, showing moderate synergy (52.02 µM2%) Viruses. 2024 Sep 14;16(9):1467
MDCK cells 0.06–1 µM 3 days Evaluation of the inhibitory effect of Laninamivir combined with Baloxavir on H1N1-PR8-I38T mutant strain, showing strong synergy (294.33 µM2%) Viruses. 2024 Sep 14;16(9):1467

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
BALB/c mice Influenza virus infection model Intranasal administration 10 mg/kg Single dose Evaluate the therapeutic efficacy of Laninamivir in influenza virus-infected mice, showing significant reduction in weight loss, mortality, and lung viral titers. J Virol. 2020 Dec 9;95(1):e01679-20

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.89mL

0.58mL

0.29mL

14.44mL

2.89mL

1.44mL

28.87mL

5.77mL

2.89mL

References

 

Historical Records

Categories